1 Profitable Stock with Exciting Potential and 2 That Underwhelm

Barchart·06/09/2026 03:20:18

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.

Profits are valuable, but they’re not everything. At StockStory, we help you identify the companies that have real staying power. Keeping that in mind, here is one profitable company that balances growth and profitability and two best left off your watchlist.

Two Stocks to Sell:

Omnicell (OMCL)

Trailing 12-Month GAAP Operating Margin: 2.7%

Driven by the vision of an "Autonomous Pharmacy" with zero medication errors, Omnicell (NASDAQ:OMCL) provides medication management automation and adherence tools that help healthcare systems and pharmacies reduce errors and improve efficiency.

Why Are We Out on OMCL?

1. Muted 5.4% annual revenue growth over the last two years shows its demand lagged behind its healthcare peers
2. Incremental sales over the last five years were much less profitable as its earnings per share fell by 6.8% annually while its revenue grew
3. Underwhelming 0.5% return on capital reflects management’s difficulties in finding profitable growth opportunities, and its falling returns suggest its earlier profit pools are drying up

Omnicell’s stock price of $41.92 implies a valuation ratio of 23.1x forward P/E. If you’re considering OMCL for your portfolio, see our FREE research report to learn more.

Solventum (SOLV)

Trailing 12-Month GAAP Operating Margin: 25.5%

Founded in 1985, Solventum (NYSE:SOLV) develops, manufactures, and commercializes a portfolio of healthcare products and services addressing critical customer and therapeutic patient needs.

Why Is SOLV Risky?

1. Core business is underperforming as its organic revenue has disappointed over the past two years, suggesting it might need acquisitions to stimulate growth
2. Projected sales for the next 12 months are flat and suggest demand will be subdued
3. Free cash flow margin dropped by 30.8 percentage points over the last five years, implying the company became more capital intensive as competition picked up

At $70.00 per share, Solventum trades at 12.1x forward P/E. Check out our free in-depth research report to learn more about why SOLV doesn’t pass our bar.

One Stock to Watch:

Crane (CR)

Trailing 12-Month GAAP Operating Margin: 17.3%

Based in Connecticut, Crane (NYSE:CR) is a diversified manufacturer of engineered industrial products, including fluid handling, and aerospace technologies.

Why Could CR Be a Winner?

1. Exciting sales outlook for the upcoming 12 months calls for 19.1% growth, an acceleration from its two-year trend
2. Performance over the past two years shows its incremental sales were extremely profitable, as its annual earnings per share growth of 21.8% outpaced its revenue gains
3. Free cash flow margin increased by 4.7 percentage points over the last five years, giving the company more capital to invest or return to shareholders

Crane is trading at $192.85 per share, or 27.1x forward P/E. Is now the time to initiate a position? See for yourself in our full research report, it’s free.

Stocks We Like Even More

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.